"‘Astounding’ Second-Chance Cancer Drug Heading For FDA Approval" - Michael Nedelman
An advisory committee recommended a new gene therapy drug, the first in its class, for approval to the US Food and Drug Administration recently. If approved by the FDA, the agency would consider it the first gene therapy to hit the market. The drug may provide a second change to some leukemia patients whose first-line drugs have failed. Joshua Brody, MD, assistant professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai said, “They’re taking some people that had incurable diseases and potentially turning them into curable diseases.” Dr. Brody has helped design trials for similar drugs. “We’ve never seen his theoretical thing, “Dr. Brody added, arguing that the chance of any adverse event happening is certainly smaller than the certain death of relapsed cancer. “It’s not an opinion. This is straightforward numbers.”
-Joshua Brody, MD, Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Scientists Unlock Promising Key to Preventing Cancer Relapse After Immunotherapy
Dec 17, 2020 View All Press ReleasesMount Sinai Researchers Make Immunotherapy Work for Treatment-Resistant Lymphoma
Aug 02, 2019 View All Press Releases